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Abstract
Immunization against amyloid-β (Aβ) peptides deposited in Alzheimer’s disease (AD) has shown considerable
therapeutic effect in animal models however, the translation into human Alzheimer’s patients is challenging. In
recent years, a number of promising Aβ immunotherapy trials failed to reach primary study endpoints. Aside
from uncertainties in the selection of patients and the start and duration of treatment, these results also suggest that
the mechanisms underlying AD are still not fully understood. Thorough characterizations of protein aggregates in AD
brain have revealed a conspicuous heterogeneity of Aβ peptides enabling the study of the toxic potential of each of
the major forms. One such form, amino-terminally truncated and modified pyroglutamate (pGlu)-3 Aβ peptide
appears to play a seminal role for disease initiation, qualifying it as novel target for immunotherapy approaches.
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Background
Alzheimer’s disease (AD) is the leading cause of demen-
tia estimated to affect ~80–131.5 million individuals
worldwide by the middle of the 21st century [1, 2]. AD is
characterized by a progressive loss of memory accom-
panied by emotional changes, hallucinations, delusions
and impaired social behavior leading to an increased
need for around-the-clock care in the final stages of the
disease [1, 3]. The disorder is considered to be devel-
oped spontaneously in the vast majority of individuals,
although studies in monozygous twins suggest a strong
genetic component [4]. The average age of onset is
within the 7th or 8th decade of life. AD is characterized
by two pathological hallmarks, extracellular amyloid pla-
ques composed of deposited β-amyloid (Aβ) peptides,
and intraneuronal neurofibrillary tangles formed from
hyperphosphorylated tau protein [4]. In a low number
of AD cases (<1 %) the disease is inherited in a domin-
ant fashion. Most of the identified familial AD (FAD)
mutations lie within the sequence of the amyloid pre-
cursor protein (APP) or in the presenilins, the proteo-
lytic machinery that liberates Aβ molecules [3, 5]. The
resulting alterations in APP processing or changes in
the biophysical properties of the resulting Aβ peptides,
lead to an early onset of the disease most frequently de-
veloped within the 5th and 6th decade of life [6, 7]; how-
ever, some rare mutations are able to cause a shift of
the age of onset as early as the 3rd decade of life [8].
Therefore, the accumulation of Aβ aggregates plays an early
and essential role in AD and is the target for immunother-
apy approaches. However, most Aβ immunization trials
have failed thus far. We suggest that one of the possible
contributing factors for study failure might be the Aβ
forms being targeted by the vaccines and/or antibodies.
Previous studies have revealed a heterogeneous mixture
of different Aβ species in human brain parenchyma
with differing amyloidogenic potential. An N-terminally
truncated and pyroglutamate-modified Aβ variant,
pGlu-3 Aβ, has gained attention due to its exceptionally
high amyloidogeneity and neurotoxicity. Here, we dis-
cuss this variant and its potential as a target for Aβ
immunization in the light of recent developments in
several general Aβ immunotherapy trials.
Main Text
The origin and pathobiology of pGlu-3 Aβ
One major pathologic hallmark of AD is the extracellu-
lar amyloid plaque. Amyloid plaque deposits were
among the fundamental findings when Alois Alzheimer
first described the neurologic disorder later named after
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him. For a long time the nature of the plaque was un-
known until it was found that a protein fragment called
amyloid-β (Aβ), generated by cleavage of the large trans-
membrane protein, amyloid precursor protein (APP),
was its main component [9]. The generation of Aβ pep-
tides is orchestrated by the consecutive cleavage of APP
by proteases termed β- and γ-secretase. Later, BACE I
was identified to be the major β-secretase while a pro-
tein complex composed of presenilin 1 (PS1), nicastrin,
APH-1 and PEN-2 was identified as γ-secretase [10, 11].
The major Aβ isoforms possess a length of 40 (Aβ40)
and 42 (Aβ42) amino acids, respectively. Following β-
secretase cleavage of the Aβ N-terminus, the C-terminal
isoforms are generated by intramembrane proteolysis by
the γ-secretase complex [12]. The major N-terminal
form of Aβ was shown to start with an aspartic acid
(amino acid 597 of the 695 amino acids long APP iso-
form) (Fig. 1) [13]. This is in line with the cleavage pat-
tern of BACE I, preferentially leading to the liberation of
Aβ peptides starting at Asp-1 [14, 15]. However, reports
published shortly after the seminal work by Glenner and
Wong [16] identifying Aβ protein, noted truncated and
blocked N-termini on Aβ molecules isolated from AD
brain [17, 18]. Later it became evident that N-terminal
truncated and pGlu-modified Aβ species (pGlu-3 Aβ) in
particular are present in large quantities in human AD
brain, which is in contrast to the vast majority of AD
mouse models, where full-length peptides are the pre-
dominant Aβ species [19, 20]. Depending on the method
of detection, the relative amount of pGlu-3 Aβ in human
brain was described between 1 % as measured by ELISA
[21] and 27 % as measured by mass spectrometry [22].
This was recently corroborated by detailed analysis of
regional and temporal appearance of general Aβ and
pGlu-3 Aβ in sporadic AD, animal models of spontan-
eous cerebral amyloidosis and transgenic mouse models.
In the human AD brain, pGlu-3 Aβ is a major species in
diffuse and compacted plaques as well as cerebral amyl-
oid angiopathy, whereas in common transgenic mouse
models, pGlu-3 Aβ is deposited only in a subset of com-
pacted plaques and vascular amyloid in later stages of
cerebral amyloidosis [23]. Since mouse models have
Fig. 1 Targeting site for pGlu-3 Aβ-specific therapeutic antibodies. Full-length Aβ is comprised of 40 or 42 amino acids (Aβ 1-40/42). The six
N-terminal amino acids of Aβ are depicted by one-letter code of amino acids and chemical structure. pGlu-3 Aβ is a truncated and post-translationally
modified variant generated by catalysis of yet unknown proteases and QC/isoQC to convert an N-terminal glutamate residue into a cyclic
5-oxo-proline ring structure (“pGlu”, “pE”). Thereby, a neoepitope is generated that is not present in full-length Aβ molecules. The interaction site of
pGlu-3 Aβ-specific antibodies is represented by the line drawn around the pGlu-modified Aβ N-terminus
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been extensively used in AD research thus far, the low
frequency of pGlu-3 Aβ in such models may have ham-
pered investigations on the contribution of these pep-
tides to amyloid pathology.
The production of truncated pGlu-3 Aβ peptides is
not fully understood. The identified β-secretase, BACE
1, preferentially generates full-length Aβ peptides start-
ing at Asp-1 and to a lesser extent N-terminally trun-
cated Glu-11 Aβ [11, 14]. However, the generation of
pGlu-3 Aβ from Asp-1 Aβ requires 2 additional modi-
fying steps, N-terminal proteolysis of the first two Aβ
amino acids followed by cyclization of glutamate at
position 3. The mechanism of glutamate cyclization has
recently been uncovered and Glutaminyl Cyclase (QC),
an aminoacyltransferase was identified as the responsible
enzyme in vitro [24] and in vivo [21] (Fig. 1). This was
unexpected, as QC preferentially converts N-terminal glu-
tamine residues into pGlu, whereas the precursor in Aβ is
glutamate. However, the substrate specificity of QC is
slightly relaxed and QC is also capable of converting,
e.g. N-terminal β-homoglutamine [25] finally leading to
the discovery of glutamate cyclization by QC under
mildly acidic conditions [24]. QC converts glutamate
residues at a 3 orders-of-magnitude lower rate constant
than N-terminal glutamine residues, but the rate en-
hancement of QC-mediated catalysis compared to
spontaneous cyclization in water is only 2 orders-of-
magnitude lower for N-terminal glutamate compared
to glutamine. Therefore, the specificity for its primary
substrate glutamine is only modest and in turn, QCs
catalytic contribution to the generation of pathologic
Aβ peptides formed from a glutamate precursor can be
considered as substantial [26].
In contrast, the mechanism of N-terminal truncation
remains elusive. It has been suggested that Aminopepti-
dase A contributes to the N-terminal truncation of full-
length Aβ peptides [27] but direct liberation of truncated
Aβ peptides by alternative pathways have also been sug-
gested [28–31].
Compared to full-length Aβ1-40 and Aβ1-42, pGlu-3
Aβ possesses a higher amyloidogeneity and toxicity. This
is reflected by a higher surface hydrophobicity, lower
solubility and a strikingly different appearance of fibrils
by electron microscopy compared to Aβ1-40 or Aβ1-42
[32, 33]. Most interestingly, pGlu-3 Aβ has been sug-
gested to act as a seed for template-induced misfolding,
reminiscent of prions [34]. Co-oligomerization of a low
amount of pGlu-3 Aβ peptides with an excess of full-
length Aβ1-42 gave rise to the same cytotoxic Aβ species
as oligomerization of pGlu-3 Aβ alone. These results
suggest that pGlu-3 Aβ oligomers transfer their cyto-
toxic nature to Aβ1-42 peptides even when present in
small quantities and therefore propagate the generation
of cytotoxic oligomers in a prion-like fashion [34]. As a
consequence, pGlu-3 Aβ molecules might play an im-
portant role for early neuronal toxicity observed in AD.
Indeed, pGlu-3 Aβ peptides are more toxic to neuronal
and glial cultures than full-length Aβ peptides [35]. In
addition, overexpression of pGlu-3 Aβ in mice leads to
neuron loss [36, 37], which is in stark contrast to the
overexpression of Aβ1-40 or 1-42. Both full-length pep-
tides failed to produce an overt neurotoxic phenotype
aside from plaque deposition in mice [38, 39]. However,
the molecular basis for the higher toxicity of pGlu-3 Aβ
is only poorly understood. A potential mechanism sug-
gests that larger pGlu-3 Aβ oligomers are formed
through faster aggregation kinetics (compared to full-
length Aβ peptides) and subsequently insert into mem-
branes, forming pore-like structures. This might lead to
higher ion permeability and altered membrane proper-
ties, which ultimately could result in a loss of cell
homeostasis [40, 41]. In addition, pGlu-3 Aβ was only
recently described to enhance lipid peroxidation in pri-
mary cortical mouse neurons, to trigger Ca2+ influx and
to facilitate the loss of plasma membrane integrity [42].
Consequently, pGlu-3 Aβ is an emerging target for
immunotherapy approaches in AD, which have previ-
ously shown considerable effects in preclinical animal
models [43]. In this regard, the relatively novel concept
of anti-pGlu-3 Aβ immunization may benefit from a
decade of experiences with immunotherapy trials
against other Aβ forms.
Immunotherapy against Aβ
Immunotherapy against Aβ peptides in AD includes
both active and passive immunization approaches [44].
The goal of active Aβ vaccines is to elicit a strong cellu-
lar and humoral antibody response through B- and T-
cells. This is commonly achieved by using an antigen,
either alone or conjugated to a non-self T helper cell
epitope, to direct the immune response towards pro-
duction of anti-Aβ antibodies, combined with an adju-
vant to induce high antibody titers. One main
advantage of this approach is a sustained immune re-
sponse that is refined through affinity maturation, thus
requiring a limited number of immunizations and mak-
ing it ideal for distribution in a large patient population.
However, caveats are the possibility of an induction of a
deleterious inflammatory T-cell response that requires
time to quench. In addition, the production of poly-
clonal antibodies makes this strategy less preferable if
specific targeting of a particular isoform or epitope of Aβ
is desired. Finally, age-related immunosenescence in the
elderly render AD patients poor antibody responders.
Passive immunotherapeutic approaches against Aβ can
be utilized to overcome some of these limitations. With
direct injection of monoclonal antibodies, immunose-
nescence is not an issue and specific targeting of a
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particular epitope or isoform of Aβ is easily achieved.
Furthermore, if adverse events should ensue, monoclo-
nal antibody infusions can be discontinued. Drawbacks
to this method include sustained production costs asso-
ciated with generating massive amounts of humanized
monoclonal antibodies, continued antibody infusions re-
quiring many visits to the doctor’s office, and the potential
of a patient developing anti-antibodies causing a neutraliz-
ing effect towards the exogenous antibody injections.
Recent active Aβ vaccine trials
The promising idea of active vaccination against Aβ
peptides came to a sudden halt in 2002, when the first
active vaccination trial in humans (AN1792) caused ab-
normalities described as a form of meningoencephalitis,
likely an autoimmune reaction, possibly to Aβ in blood
vessel walls, in approximately 6 % of enrolled moderate-
to-severe AD patients [45, 46]. The side effects included
the presence of lymphocytes in the CSF and focal white
matter abnormalities on imaging [45]. While the exact
causes of these adverse events were never definitively
understood, probable causes may have been the use of
full-length Aβ1-42 as an the immunogen, which has since
been shown to display several T-cell epitopes particularly
in the region between amino acids 15 and 42, the use of
Q21, a highly Th1 biased adjuvant, or the formulation
change of adding polysorbate 80 for stability [47–49].
Besides the observed adverse events, autopsies of cases en-
rolled in AN1792 showed evidence of amyloid removal,
although without any improvement in dementia [50].
Therefore, second-generation active Aβ vaccines are
under development to overcome the pitfalls observed
in the AN1792 trial. Active vaccines brought to early
stage clinical trials aim to exclusively target B-cell epi-
topes to generate a robust humoral response, while
reducing the chance of an autoimmune T-cell pro-
inflammatory response through the use of N-terminal
Aβ fragments, mimotope and neoepitope vaccines, as
well as phage and virus-like particle vaccines [44].
In 2013, Pfizer and Janssen completed phase II clinical
trials in 360 mild to moderate AD patients testing the
safety and efficacy of their ACC-001 (vanutide cridificar)
active vaccine (https://clinicaltrials.gov), which consists
of an Aβ N-terminal fragment (Aβ 1-7) conjugated to an
immuno-stimulatory carrier protein with and without
QS21 as adjuvant [51]. Recently, the safety outcome of a
study in Japanese subjects with mild to moderate AD
was published [52]. High antibody titers were reported
along with a number of mild to severe adverse events
[52]. The clinical development of this treatment was dis-
continued, in 2015, for reasons that have not been
disclosed.
Furthermore, in 2012, Novartis reported its phase I
clinical data in patients with mild to moderate AD
immunized with CAD106, a novel vaccine consisting of
multiple copies of Aβ 1-6 coupled to a coat protein of
bacteriophage Qβ. After three subcutaneous injections
of 50 μg CAD106 in cohort 1 or 150 μg CAD106 in co-
hort 2, 67 and 82 %, respectively, of treated patients had
generated significant anti-Aβ serum antibodies levels
classifying them as responders. While no alterations in
CSF Aβ or whole brain MRI volume were observed be-
tween CAD106 and placebo groups, these studies were
not statistically powered to detect changes in biomarkers
[53]. Subsequent phase II clinical trials with CAD106
have been completed and were first reported at the 2014
Alzheimer’s Association International Conference (AAIC)
in Copenhagen, Denmark. There, it was reported, that
strong serological responders bound less florbetapir at
78 weeks than at baseline. No changes in CSF Aβ were
observed, but CSF p-tau declined in strong antibody re-
sponders (www.alzforum.org). Additional phase II clinical
data were reported only recently [54]. Immunization of
patients using 150 μg CAD106 led to 63.8 % serological
responders. In addition, 74.5 % adverse events in treated
patients compared to 63.3 % adverse events in placebo
group were reported. Amyloid-related imaging abnormal-
ities (ARIA) corresponding to microhemorrhages were
observed in 3 patients treated with CAD106. No vaso-
genic edemas were observed [54]. Novartis and the
Banner Health Institute have begun phase II/III trials
testing this novel vaccine with a BACE I inhibitor in
pre-symptomatic, cognitively healthy adults, who have
two copies of the ApoE4 gene, making them more at
risk of developing AD, in a trial known as the Alzhei-
mer’s Prevention Initiative APOE4 trial, expected to
reach completion in 2023 (www.alzforum.org).
Also, currently in clinical phase I/II trials is AC Im-
mune’s ACI-24 liposome-based vaccine using Aβ1-15,
which aims to produce β-sheet conformation-specific
antibodies (www.acimmune.com). AC Immune, together
with the LuMind Research Down Syndrome Foundation,
have brought this vaccine into phase I trials in 24 adults
with Trisomy 21-positive Down Syndrome, the results of
which are expected in 2019 (https://clinicaltrials.gov).
In addition, UB-311 (United Biomedical), targeting
Aβ1-14, has shown safety and efficacy in phase I clin-
ical trials with a phase II study currently recruiting pa-
tients with mild AD (https://clinicaltrials.gov) and V950
from Merck, an N-terminal Aβ fragment conjugated to
an aluminum-containing adjuvant with or without
ISCOMATRIX, has completed a phase I clinical trial.
Finally, an active vaccine developed by AFFiRiS AG,
Austria stimulating an immune response against Aβ by
short peptides obtained by molecular mimicry (“mimo-
topes”) [55] has completed phase II clinical trials. Their
front-runner AD02 stimulates an immune response di-
rected towards the N-terminus of unmodified Aβ species
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(https://clinicaltrials.gov). At a press briefing in June
2014, AFFiRiS reported first results on the efficacy of
AD02 showing that AD02 did not reach primary or sec-
ondary outcome measures (www.alzforum.org). According
to AFFiRiS (12th International Conference on Alzheimer’s
and Parkinson’s Diseases and Related Neurologic Disor-
ders, AD/PD 2015, Nice), placebo-treated patients showed
less cognitive decline accompanied by less hippocampal
shrinkage than AD02-treated patient. Whether the ingre-
dients of the placebo formulation are indeed responsible
for the observed effects remains to be determined. Never-
theless, the same formulation was also used for applica-
tion of AD02, confusing the potential causes of this trial
failure (www.alzforum.org).
Latest developments in passive Aβ immunotherapy
Following the termination of the AN1792 trial, signifi-
cant effort has gone into the development and testing
of monoclonal antibodies for passive Aβ immunization.
The first antibody in clinical trials, bapineuzumab
(Janssen and Pfizer), is the humanized version of 3D6, an
IgG1 mouse monoclonal specific for an N-terminal Aβ
epitope (Aβ1-5) and it only recognizes Aβ peptides with
an aspartic acid residue at the N-terminus [56]. Although
phase II clinical trials in mild-to-moderate AD did not ini-
tially present clear clinical benefits, post-hoc analysis re-
vealed that a subgroup of ApoE4 non-carriers showed
some evidence of clinical improvement. Furthermore, 12/
124 (9.7 %) of bapineuzumab-treated patients experienced
transient and reversible edema [also known as ARIA-E],
which was more frequent in ApoE4 carriers with one copy
of the allele (7.1 %) and two copies of the allele (33.3 %)
compared to non-carriers (4.3 %). In addition, 11/12
edema cases occurred at a dose >1 mg/kg [57]. Whether
the observed edema is vasogenic or due to other mech-
anisms such as microglial activation requires further
studies. Target engagement detected by 11C-PiB PET
imaging showed evidence for a stabilization of Aβ bur-
den in bapineuzumab-treated subjects compared to an
increase in the placebo-treated individuals [58]. These
findings and modest clinical benefits warranted contin-
ued evaluation in phase III trials. Unfortunately, two
large phase III clinical trials reported no significant
clinical benefits, which led to the termination of all
phase III bapineuzumab clinical trials. Recent biochem-
ical analyses of the brains from 3 patients treated with
bapineuzumab showed a trend for reduction in Aβ42
accompanied by an increase in Aβ40 leading to an
overall reduction in the Aβ42/40 ratio. These findings
highlight a dynamic homeostatic balance of Aβ, obvi-
ously altered by bapineuzumab treatment [59]. In
addition, AAB-003, a derivative of Bapineuzumab with
altered effector function was tested in Phase I studies
with results pending (www.alzforum.org).
Eli Lilly’s solanezumab is the humanized version of
m266, an IgG1 monoclonal antibody that recognizes an
epitope within Aβ16-24. It is purported to preferentially
recognize soluble Aβ species and not fibrillar Aβ and
has been shown to increase both plasma and CSF Aβ
[60]. Solanezumab was tested in phase III clinical trials
and failed to show significant improvement in primary
outcomes in the phase 3 trials, EXPEDITION 1 and EX-
PEDITION 2 [61]. Secondary analysis in pooled subjects
from both trials with mild AD showed less cognitive and
functional decline when treated with solanezumab com-
pared to placebo. In contrast, patients with moderate
AD did not benefit from solanezumab treatment [62].
Unlike bapineuzumab, solanezumab has not been associ-
ated with ARIA-E or microhemorrhages [60] and is well
tolerated at doses up to 400 mg administered weekly. An
additional phase III study testing solanezumab at
400 mg every 4 weeks for 76 weeks in mild AD patients
(EXPEDITION III), is currently ongoing and expected to
reach completion in 2018 (https://clinicaltrials.gov).
Most recently, aducanumab, a co-development of Neur-
immune (Switzerland) and Biogen (USA) has gained much
attention. Aducanumab (BIIB037) results from reverse
translational medicine and is not a humanized mouse
monoclonal antibody. Instead, it is a fully human IgG1
monoclonal antibody isolated from healthy aged donors
representing cognitively healthy aging (www.alzforum.org).
As presented at the 11th International Conference on
Alzheimer’s and Parkinson’s Diseases and Related
Neurological Disorders held in 2013 in Florence, Italy,
aducanumab binds fibrillar amyloid and is able to re-
duce plaque burden in AD mice. Aducanumab was
tested in prodromal or mild AD and showed a dose-
dependent reduction of Aβ-PET signal almost to
threshold levels and slowing of cognitive decline at the
highest dose (10 mg/kg) as presented at AD/PD 2015 in
Nice and the Alzheimer’s Association International
Conference (AAIC) 2015 in Washington DC. The ob-
served effect on cognitive decline was dose-dependent.
ARIA-E was reported to increase with dose and ApoE4
carriage with 55 % incidence in homozygous ApoE4
carriers (www.alzforum.org). Nevertheless, this repre-
sents a breakthrough in AD immunotherapy and the
data encouraged the development team to take aduca-
numab directly to phase III clinical studies.
In addition to the clinical development of monoclonal
Aβ antibodies, consortia were established to study the
effect of preventive passive immunization in different
study populations. In this regard, the “Dominantly Inher-
ited Alzheimer’s Network” (DIAN) is testing treatments
in patients with FAD mutations that puts them at a
greater risk for developing AD than the general popula-
tion. The monoclonal antibodies solanezumab (Lilly)
and gantenerumab (Roche) were chosen as the two
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investigational antibodies. Gantenerumab, an IgG1 anti-
body, recognizes two epitopes in Aβ. One lies within the
N-terminus and another within the mid-region of Aβ.
Gantenerumab was further shown to preferentially bind
fibrillar Aβ [63]. This study is scheduled for completion
at the end of 2016.
Furthermore, the “Alzheimer’s Prevention Initiative”
(API) is currently enrolling 300 Columbian individuals
harboring an autosomal-dominant E280A PS1 muta-
tion, which has been associated with early-onset AD
[64, 65]. Because of its IgG4 backbone designed to en-
gage microglial-mediated phagocytosis of Aβ but not to
induce a pro-inflammatory response, crenezumab (Genen-
tech) has been selected. Crenezumab is the humanized
version of antibody mMABT generated by immunizing
mice with a liposome-coupled N-terminal fragment of Aβ
(Aβ 1-15) termed AC-01 by the Switzerland-based com-
pany AC Immune [66, 67]. Crenezumab was described to
bind different aggregated forms of Aβ, including oligo-
mers and fibrils and to possess a low affinity for Aβ
monomers [67].
Finally, unlike the two aforementioned initiatives in
FAD subjects, the “Anti-Amyloid Treatment for Asymp-
tomatic Alzheimer’s Disease” (A4) is enrolling 1000 sub-
jects between 65–85 years of age w/o dominantly
inherited early onset AD mutations, who exhibit amyloid
in brain by PET imaging but are otherwise cognitively
normal. This study targets people that are at risk for
developing sporadic AD and represents the majority of
the AD population. Because of its known safety profile
and evidence of modest cognitive benefit in mild AD
patients, solanezumab was chosen for the A4 trial
(www.alzforum.org).
Rationale for immunization against pGlu-3 Aβ
Most of the Aβ immunotherapy clinical trials have not
reached primary endpoints thus far, although some posi-
tive effects were observed in post-hoc analyses, e.g. in
the Solanezumab Expedition Trials. Aside from known
problems with selecting the right study population and
the optimal cognitive stage of a patient for starting treat-
ment, current immunotherapy strategies may not be tar-
geting Aβ peptides with high toxic potential such as
pGlu-3 Aβ [34]. In this regard, pGlu-3 Aβ appears to be
an attractive novel target for Aβ vaccination approaches
as Aβ1-40 and Aβ1-42 are products of normal APP
turnover [68]. In addition, Aβ is produced at similar
levels by young and aged individuals [69]. Its production
rate in healthy volunteers and AD patients does not sig-
nificantly differ, e.g. Aβ42 is generated with a rate of
6.7 %/h in non-AD and 6.6 %/h in AD patients as mea-
sured by the increase of 13C6-leucine labeled Aβ in CSF
over time [70]. Therefore, it is reasonable to consider
Aβ1-40 and Aβ1-42 as physiologic peptides, although
their exact biologic role is still not well understood. Re-
cent investigations have shown an anti-microbial activity
of Aβ as well as an importance for neuronal physiology
[71, 72]. Thus, active vaccination against full-length Aβ
peptides early in life might eliminate an important mol-
ecule of innate immunity and neuronal physiology with
unknown outcome.
In contrast to the physiologic generation of Aβ1-40 and
Aβ1-42 peptides, pGlu-3 Aβ, the result of a significant
side-reaction of QC, has a dramatic influence on the amy-
loidogeneity and toxicity of the Aβ molecule. Therefore,
pGlu-3 Aβ represents a solely non-physiologic neoepitope
(Fig. 1) that could be targeted by different immunotherapy
approaches, sparing the presumably physiologic Aβ mole-
cules 1–40 and 1–42.
Active vaccination against pGlu-3 Aβ
The development of second-generation active vaccines
was initiated after failure of the AN1792 trial, however
clinical testing has not caught up with extent of passive
immunization clinical studies performed by peripheral
application of humanized anti-Aβ antibodies. Thus, the
reports on active vaccination against pGlu-3 Aβ are
scarce and publicly reported clinical development is cur-
rently limited to a single biopharmaceutical company,
AFFiRiS AG (Austria). Here, the active pGlu-3 Aβ vac-
cine (“mimotope”) was obtained by molecular mimicry
resulting in an unrelated peptide stimulating antibody
production against pGlu-3 Aβ (Table 1) [55]. This strat-
egy circumvents a T-cell response suspected of causing
clinical side effects in the AN1792 trial. Although no
peer-reviewed publications are available for the preclin-
ical testing of anti-pGlu-3 Aβ mimotopes, according to a
published patent, the company claims a 38 % reduction
in the area occupied by amyloid plaques in Tg2576 mice
treated (s.c.) over 6 months using an anti-pGlu-3 Aβ
mimotope with aluminum hydroxide (ALUM) as an ad-
juvant. The mice were sacrificed at 13 months of age
and plaque area was determined by an Aβ40/42-specific
antibody (Mandler M. et al. (2011) US Patent Applica-
tion No: 20110097351). A Phase 1 clinical trial in mild
AD patients of the active vaccine including the pGlu-3
Aβ mimotope and alum adjuvant, AD03, was completed
in 2011 with promising results, followed by a Phase 1b
study that was terminated in 2013 due to organizational
reasons (https://clinicaltrials.gov). The outcome of the
study has not been disclosed thus far.
At the Society for Neuroscience meeting held in San
Diego in 2010, our own group reported the active vac-
cination of 6-month-old J20 mice with the N-terminal
Aβ fragment pGlu-3–9 coupled to KLH in comparison
to an aged 3:1 mixture of Aβ1-40 and Aβ1-42, each with
CFA/IFA adjuvant (Table 1). J20 mice first start to de-
velop pGlu-3 Aβ containing plaques at 6 months of age,
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albeit in low quantities [20]. Mice were immunized
(i.p.) on days 0, 14 and 28 followed by monthly injec-
tions for 8 months and generated high titers of anti-
bodies specific for the N-terminus of their respective
antigens. Both vaccines resulted in a significant reduction
of amyloid plaques, indicating that pGlu-3 Aβ-targeted ac-
tive immunization prevented deposition of both pGlu-3
Aβ and general Aβ with heterogeneous N-termini [73].
This underlines the seeding capacity of pGlu-3 Aβ and is
in line with observations made by application of QC-
specific inhibitors preventing pGlu-3 Aβ formation [21].
Finally, active vaccination of rabbits using pGlu-3
Aβ42 resulted in antibodies exclusively detecting this
Aβ isoform (Table 1). No cross-reactivity was observed
to Aβ1-42 or pGlu-11 Aβ [74]. The immuno-dominant
region of pGlu-3 Aβ was identified within the N-
terminus with no cross-reactivity to unmodified pep-
tides starting with N-terminal glutamate [74]. This is in
contrast to active vaccination using Aβ1-40 or Aβ1-42,
where the immuno-dominant epitope was represented
by the amino acid sequence EFRH in the N-terminal re-
gion of full-length Aβ [75]. These data are corroborated
by our own observations wherein immunization with
pGlu-3–9-KLH dominantly produced pGlu-3 Aβ spe-
cific antibodies whereas immunization with Aβ1-40/42
produced N-terminal (Aβ 1-15) specific antibodies.
Aside from AFFiRiS’s AD03 mimotope vaccine, as far
as we are aware, no other active anti-pGlu-3 Aβ vaccine
has progressed to clinical development to date.
Passive immunization against pGlu-3 Aβ
Passive anti-pGlu-3 Aβ immunotherapy has been more
frequently reported in the literature than active vaccin-
ation although the total number of publications is still
very low. The first report on passive pGlu-3 Aβ im-
munotherapy was published in 2010 [76]. Thomas Bayer
at the University of Goettingen (Germany) generated a
novel IgG2b monoclonal antibody (9D5) preferentially
targeting oligomeric aggregates of pGlu-3 Aβ (Table 1)
and demonstrated that passive immunization (i.p.) of
250 μg 9D5 in 4.5-month-old 5XFAD mice over 6 weeks
reduced hippocampal and cortical total Aβ, Aβ40, Aβ42
and pGlu-3 Aβ plaque load and intracellular pGlu-3 Aβ
oligomers [76]. The study further showed a significant
reduction of pGlu-3 Aβ in TBS and SDS fraction of
brain lysates detected by ELISA. 5XFAD mice display
general Aβ deposition as early as 1.5 months of age in
cortical layer V and the subiculum. Detection of pGlu-3
Aβ starts at 4 months of age in focal plaques throughout
cortical layer V and the subiculum, followed by detection
in the granule cell layer of the dentate gyrus at 6 months
of age, and pGlu-3 Aβ positive focal deposits throughout
the entire brain at 9–12 months of age [23]. Therefore,
the study published by Bayer and colleagues started
treatment around the onset of first pGlu-3 Aβ depos-
ition but after the onset of general Aβ deposition and
therefore, can be considered a prevention trial.
Two pilot studies published in 2012 by our own lab
further strengthened the feasibility of passive pGlu-3
Aβ immunization (Table 1) [77]. Here, APP/PS1ΔE9
mice underwent preventive and therapeutic passive
immunization using a novel pGlu-3 Aβ specific antibody
(07/1, IgG1) developed by Probiodrug AG (Germany). In
APP/PS1ΔE9 mice, general Aβ deposition starts at ap-
proximately 5 months of age in the hippocampus with
a subset of plaques also positive for pGlu-3 Aβ. At
14 months of age, pGlu-3 Aβ is found in diffuse and
focal deposits in cortex, hippocampus and cerebellum.
By 24 months of age, these mice display abundant
pGlu-3 Aβ immunoreactivity of plaques within hippo-
campus and a subset of plaques in the neocortex [23].
The pilot prevention trial was started in mice at 5–6
months of age, at the onset of plaque deposition. Pas-
sive immunization (i.p.) with 200 μg of 07/1 over
32 weeks resulted in a significant reduction in the de-
position of general Aβ and pGlu-3 Aβ and Thioflavin
S-positive fibrillar Aβ in the hippocampus as detected
by immunohistochemistry (IHC). In addition, signifi-
cant reductions in general Aβ and pGlu-3 Aβ deposition
were observed in the cerebellum, an area prone to plaque
deposition in this model [23]. In contrast to the study from
Wirths et al. [76], we observed no significant reduction of
Table 1 Summary of preclinical results obtained by active and passive vaccination
Ag/Ab AD Model Treatment Effect Ref.
Active vaccination
pGlu-3 mimotope Tg2576 Preventive Reduced plaques USPTO No.: 20110097351
pGlu-3-9-KLH J20 Preventive Reduced plaques [73]
pGlu-3 Aβ42 Rabbit (WT) - - [74]
Passive vaccination
9D5 5XFAD Preventive Reduced plaques and Aβ peptides [76]
07/1 APP/PS1ΔE9 Preventive & Therapeutic Reduced plaques; no change in Aβ peptides [77–80]
mE8 PDAPP Therapeutic No change in plaques; reduced Aβ peptides [83]
Ag Antigen, Ab Antibody, Ref. Reference, USPTO US Patent and Trademark Office
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pGlu-3–42 or total Aβ42 measured by ELISA in guanidine
HCl-extracted hemibrains. The reduced plaque load ob-
served in the pilot passive immunization prevention trial
was further validated in a larger study by our lab in which
cognitive performance of 07/1-vaccinated APP/PS1ΔE9
mice was normalized to wildtype levels following treat-
ment [78].
The pilot therapeutic trial in plaque-rich 23-month-
old mice using weekly 07/1 antibody injections (200 μg)
for 7 weeks demonstrated a plaque-lowering effect [77].
A more recent larger study from our lab has confirmed
and extended these results to include behavioral ana-
lyses [79–81]. Interestingly, we demonstrated in our
pilot studies a similar strong reduction of amyloid
plaque load and fibrillar Aβ in aged APP/PS1ΔE9 mice
immunized for only 7 weeks compared to that in the
prevention study over 32 weeks in young mice. This
was even more pronounced in the cerebellum, an area
of late plaque deposition in this model, suggesting that
the antibody may be most efficacious in preventing
and/or removing newly deposited plaques. This result is
consistent with the change in Aβ40/42 ratio observed
in patients immunized with bapineuzumab [59], and
suggests that passive immunization using a pGlu-3 Aβ
antibodies is able to change parameters of pathology
long after the onset of amyloid deposition. Importantly,
unlike previous reports that passive immunization with
N-terminal Aβ antibodies increased the incidence of
microhemorrhages in aged APP23 mice [82], we have
observed no increase in microhemorrhages in 07/1
pGlu-3 Aβ-immunized APP/PS1ΔE9 mice to date.
A recent publication from researchers at Eli Lilly and
Company described the effects of a novel pGlu-3 Aβ
specific IgG2a antibody (mE8) on Aβ levels and plaque
pathology in aged PDAPP mice (Table 1) [83]. The re-
sults were compared to the 3D6 IgG1 antibody, which
represents the murine precursor of bapineuzumab.
Aged PDAPP mice (23–24 months) were treated for
3 months with 12.5 mg/kg mE8 and 3D6. At the start
of treatment the mice showed a similar proportion of
pGlu-3-modified Aβ42 as observed in human AD brain
tissue. The applied dose translated into approximately
500 μg antibody/mouse, which is 2.5X the amount used
in our own pilot study. DeMattos et al. were able to
show a significant reduction of guanidine-HCl extract-
able Aβ1-42 in hippocampus. The effect was dependent
on the effector function of the respective IgG molecule,
with mE8-IgG2a being more effective than mE8-IgG1.
This was in line with the abilities of different mE8-IgG
subclasses to stimulate ex vivo phagocytosis of Aβ by
primary murine microglia cells. The effect on Aβ1-42
was less pronounced in cortex, where only treatment
with mE8-IgG2a reached statistical significance. In
addition, quantification of the total plaque area by
immunohistochemical staining failed to show differ-
ences among the treatment groups although the au-
thors reported a reduction of existing “plaque load” by
mE8 treatment using biochemical measurements
(ELISA) [77, 83]. This is in contrast to our published
pilot study, where significant reductions in both general
and pGlu-3 Aβ labeled plaques were observed [77].
More recently, Lilly reported at the Alzheimer’s Associ-
ation International Conference held in Copenhagen in
2014 that co-treatment of mice with their pGlu-Aβ spe-
cific antibody mE8 together with a BACE I-inhibitor
cleared both compacted and diffuse plaques in aged
PDAPP mice, suggesting that the BACE I inhibitor led
to a reduction of diffuse plaques while the pGlu-Aβ
antibody to a reduction of compacted plaques. The
combination cleared both types of amyloid deposits
suggesting a synergistic effect of such combination
therapy (www.alzforum.org). The clinical candidate is
termed LY3002813 and an ongoing clinical phase 1 trial
is aiming at determining safety and tolerability in up to 100
healthy participants as well as in subjects with MCI and
mild to moderate AD patients (https://clinicaltrials.gov).
Conclusions
AD brains contain considerable amounts of pGlu-3 Aβ
although absolute values differ between the methods
used for quantification. Results obtained by ELISA
showed that pGlu-3 Aβ42 accounts for less than 1 % of
total Aβ42 [21]. Other studies using mass spectrometry
calculated quantities of up to 27 % of all Aβ peptides to
start with an N-terminal pGlu-residue in temporal cor-
tex [22]. In cotton wool plaques deposited in patients
carrying the PS1 V261I mutation, N-truncated and
pGlu-modified Aβ peptides represent the major species
[6]. Therefore it is unclear, why pGlu-3 Aβ peptides did
not gain much attention. One explanation might be
that the pGlu-modification was frequently considered
as secondary reaction occurring later in disease pro-
gression [84].
Although the absolute amount of deposited pGlu-3
Aβ varies between different reports, preclinical studies
aiming at reducing pGlu-3 Aβ peptides in brains of
AD-like mouse models have shown remarkable success.
The ability to reduce general Aβ deposition by pGlu-3
Aβ-specific immunotherapy is comparable to the efficacy
seen with immunization targeting full-length Aβ [83].
It has been suggested that pGlu-3 Aβ is a seeding spe-
cies for general Aβ deposition. Furthermore, pGlu-3 Aβ
appears to cause template-induced misfolding of other
Aβ molecules already apparent in very low quantities
[34]. Active and passive immunization approaches as
well as pharmacologic inhibition of pGlu-3 Aβ formation
by QC inhibitors in mouse models with considerable
lower pGlu-3 Aβ deposition compared to humans [20]
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now substantiates these biophysical and cell biological
studies [21, 33, 34]. Due to its nature as a by-product of
a catalytic side-reaction of QC, pGlu-3 Aβ further repre-
sents a true Aβ neoepitope that only correlates with
deleterious effects on brain physiology.
Despite these encouraging results, immunotherapy
against pGlu-3 Aβ faces similar challenges as ap-
proaches directed against other Aβ isoforms. These in-
clude: (I) Passively administered pGlu-3 Aβ antibodies
need to efficiently cross the blood brain barrier to reach
target molecules in the brain. (II) Treatment needs to
be initiated as early as possible since active and passive
immunization in patients already diagnosed with AD
has been incapable of stopping disease progression thus
far. (III) Active immunization against pGlu-3 Aβ in AD
patients would also face the problem of immunosenes-
cence leading to a certain percentage of non-responders.
(IV) The application of humanized monoclonal antibodies
may induce an immune response against the treatment
antibodies reducing their efficacy. (V) pGlu-3 Aβ appears
to be specifically present in brain parenchyma and absent
in detectable amounts in body fluids such as CSF or
plasma [83]. Given its neurotoxic nature, it is unclear what
adverse effects are to be expected when this exceptionally
toxic variant is mobilized from deposits of PiB-positive in-
dividuals by Aβ immunotherapy. On the other hand, the
absence of detectable levels of pGlu-3 Aβ in plasma may
reduce peripheral saturation thereby allowing more anti-
bodies for delivery to the brain parenchyma.
In the future, the current clinical trials (DIAN, API,
A4) that aim to prevent AD symptoms in people at risk,
will help to further illuminate the way for AD immuno-
therapy, including immunization targeting pGlu-3 Aβ.
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